On February 19, CSPC Innovation Pharmaceutical Co., Ltd. (Stock Name: Sinoway, Stock Code: 300765.SZ) issued an announcement, stating that its holding subsidiary CSPC Megalith Biopharmaceutical Co., Ltd. (hereinafter referred to as " Megalith Biopharmaceutica") has entered into an agreement with Radiance Biopharma, Inc. (hereinafter referred to as "Radiance Biopharma").
Under the terms of the agreement, Radiance Biopharma will obtain the exclusive rights for the development and commercialization of the SYS6005 project (hereinafter referred to as "the Product"), independently researched, developed and owned with independent intellectual property rights by CSPC Megalith, in the United States, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, Australia and Canada (hereinafter collectively referred to as the "Licensed Territory"). It will also acquire the exclusive manufacturing rights for the Product pursuant to subsequent clinical and commercial supply agreements.
Pursuant to the agreement, Radiance Biopharma shall pay an upfront payment of 15 million US dollars to Jushi Biopharma. Radiance Biopharma, its affiliates or sub-licensees shall pay corresponding milestone payments to CSPC Megalith based on the progress of development, marketing and sales within the licensed territory. The cumulative development milestone payments shall not exceed 150 million US dollars, and the cumulative sales milestone payments shall not exceed 1.075 billion US dollars. During the applicable royalty term of the licensed products, Radiance Biopharma shall pay royalties to CSPC Megalith at the royalty rate corresponding to the total net sales of all licensed products in the licensed territory as stipulated herein.
Developed by CSPC Megalith, SYS6005 is a monoclonal antibody-drug conjugate (ADC). It can bind to specific receptors on the surface of tumor cells, enter cells through endocytosis and release payload toxins, thereby exerting anti-tumor cell killing effects.Classified and filed as a Class 1 therapeutic biological product, SYS6005 has been approved for the indication of advanced tumors. It is expected to be applicable to the treatment of hematological malignancies, ovarian cancer, non-small cell lung cancer and other tumor types.
SYS6005 adopts CSPC Megalith’s proprietary enzyme-catalyzed site-specific antibody conjugation technology. Through a stable conjugation design, it effectively reduces the systemic exposure of the mitotic inhibitor MMAE. The product precisely targets ROR1-expressing cancer cells and releases the cytotoxic payload, thereby lowering drug-related adverse reactions.Compared with normal tissues, ROR1 is highly overexpressed in a variety of hematological malignancies and solid tumors, and its expression level is closely correlated with disease progression and treatment response, making ROR1 an attractive therapeutic target for anti-cancer drug research and development.SYS6005 is engineered with a homogeneous DAR distribution, proprietary linkers with superior stability, and an optimized low drug-to-antibody ratio. These features enhance blood stability and enable site-specific drug release at tumor lesions, leading to an improved safety profile and therapeutic efficacy. In December 2024, SYS6005 was approved for clinical trials in China.
Radiance Biopharma focuses on developing an antibody-based oncology pipeline, including monospecific and bispecific antibody-drug conjugates (ADCs), to treat cancers and address other unmet medical needs. The company is headquartered in Boston, Massachusetts, the United States.
This collaboration leverages Radiance Biopharma’s R&D strengths in antibody-based cancer therapeutics and its overseas market resources to advance the development and commercialization of SYS6005. It will help enhance the Company’s overall competitiveness and align with its long-term development strategy of building a leading innovative biopharmaceutical platform.